Changing Consumption Patterns Will Undermine Margins Despite Molson Coors Partnership

Key Takeaways

• Rising health awareness and economic pressures are reducing demand for premium mixers, threatening Fevertree's market expansion and sustaining margins.
  
• Overdependence on core products and partners, amid growing competition, risks stalling growth and further eroding profitability.
  
• Strategic partnerships, market share gains, premium brand positioning, product innovation, and operational efficiency drive Fevertree's prospects for growth, profitability, and earnings resilience.

Catalysts

About Fevertree Drinks

Engages in the development and sale of mixer drinks in the United Kingdom, the United States, Europe, and internationally.

What are the underlying business or industry changes driving this perspective?

• Fevertree's future revenue growth faces structural risk from shifting consumer behavior as increased health consciousness drives a long-term decline in both sugary and alcoholic beverage consumption, which may result in lasting volume contraction for mixers and threaten the company's ability to expand its total addressable market.
  
• Emerging inflationary pressures and persistently weak consumer spending, especially in developed markets like the UK and Europe, are causing consumers to favor lower-priced or private label alternatives, undermining Fevertree's premium pricing power and likely shrinking gross margins in the years ahead.
  
• Despite investments in portfolio innovation, Fevertree remains heavily reliant on its core premium mixer segment; if the shift toward ready-to-drink alcoholic beverages accelerates or non-mixer soft drink categories do not scale as hoped, the business risks stagnation, with revenue growth plateauing and earnings resilience deteriorating.
  
• The partnership with Molson Coors is intended to secure U.S. profit growth, but an overreliance on one strategic partner may expose Fevertree to unfavorable contract renegotiations, possible margin dilution if guaranteed royalties fail to match rising costs, and slower-than-expected U.S. market penetration, all of which could weigh on future profits.
  
• Intensifying competition from multinational beverage giants, expanding craft brands, and consolidating retail channels threatens Fevertree's global market share, increasing the likelihood of higher marketing spend and distribution costs, further eroding operating margins and net earnings over the medium to long term.

Fevertree Drinks Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Fevertree Drinks compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Fevertree Drinks's revenue will grow by 7.0% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from 7.0% today to 12.0% in 3 years time.
• The bearish analysts expect earnings to reach £47.9 million (and earnings per share of £0.44) by about June 2029, up from £22.6 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as £62.8 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 18.4x on those 2029 earnings, down from 41.4x today. This future PE is lower than the current PE for the GB Beverage industry at 20.6x.
• The bearish analysts expect the number of shares outstanding to decline by 2.09% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.38%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The transformational long-term partnership with Molson Coors provides Fevertree with guaranteed royalty profits and significantly reduces U.S. working capital requirements, likely leading to improved earnings quality, consistent cash generation, and a stronger balance sheet over the coming years.
  
• Fevertree is continuing to gain share in key global markets, with double-digit constant currency revenue growth in the U.S., strong share gains in both Tonic and Ginger Beer, and increasing penetration in large regions like Australia and Canada, which supports robust top-line revenue growth potential.
  
• Secular trends in premiumization of mixed drinks, the rise of at-home and on-the-go consumption, and the shift toward sophisticated nonalcoholic beverages align directly with Fevertree's strengths as a premium, highly recognized brand, likely sustaining or increasing long-term demand and therefore supporting both revenue and margin growth.
  
• Innovation in the product portfolio, including rapid expansion into the non-Tonic, cocktail mixer, adult soft drink, and ready-to-drink segments, positions Fevertree to diversify revenue streams, tap into fast-growing categories, and maintain pricing power, which can boost future revenue and overall earnings resilience.
  
• Ongoing supply chain optimization, gross margin recovery (from lower glass and energy costs, pricing actions, and ramping local production), and strong overall cash conversion offer structural potential for further improvements in operating margins and net income, which could underpin long-term share price strength.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Fevertree Drinks is £6.3, which represents up to two standard deviations below the consensus price target of £9.52. This valuation is based on what can be assumed as the expectations of Fevertree Drinks's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £15.0, and the most bearish reporting a price target of just £6.3.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be £398.5 million, earnings will come to £47.9 million, and it would be trading on a PE ratio of 18.4x, assuming you use a discount rate of 7.4%.
• Given the current share price of £8.16, the analyst price target of £6.3 is 29.6% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.